Production (Stage)
Sensei Biotherapeutics, Inc.
SNSE
$0.295
-$0.014-4.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.55M | 2.13M | 3.19M | 3.20M | 3.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.27M | 6.62M | 7.82M | 7.79M | 8.73M |
| Operating Income | -7.27M | -6.62M | -7.82M | -7.79M | -8.73M |
| Income Before Tax | -6.86M | -7.77M | -7.25M | -7.14M | -7.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.86M | -7.77M | -7.25M | -7.14M | -7.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.86M | -7.77M | -7.25M | -7.14M | -7.99M |
| EBIT | -7.27M | -6.62M | -7.82M | -7.79M | -8.73M |
| EBITDA | -7.24M | -6.29M | -7.49M | -7.46M | -8.40M |
| EPS Basic | -0.27 | -0.31 | -0.29 | -0.28 | -0.32 |
| Normalized Basic EPS | -0.18 | -0.16 | -0.18 | -0.18 | -0.20 |
| EPS Diluted | -0.27 | -0.31 | -0.29 | -0.28 | -0.32 |
| Normalized Diluted EPS | -0.18 | -0.16 | -0.18 | -0.18 | -0.20 |
| Average Basic Shares Outstanding | 25.19M | 25.17M | 25.15M | 25.10M | 25.05M |
| Average Diluted Shares Outstanding | 25.19M | 25.17M | 25.15M | 25.10M | 25.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |